News

Why Novo Nordisk Stock Imploded This Week
Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...
Novo Nordisk Cut Its Outlook and Named a New CEO. Its Stock Is Plummeting
U.S.-listed shares of Novo Nordisk (NVO) sank roughly 20% in premarket trading after the Danish drugmaker cut its full-year ...
Novo Nordisk stock posts worst week since 2021, but analysts see a bigger problem ahead
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
Novo Nordisk: Is This An Overreaction Or The End Of The GLP-1 Fairy Tale?
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
Opinion
Novo Nordisk’s Weight Loss Lesson
Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.
Stock Movers: Novo Nordisk, Palo Alto, Union Pacific
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Instant View: Reaction to new Novo Nordisk CEO, profit warning
Novo Nordisk on Tuesday appointed insider Mike Doustdar as its new chief executive after the Danish obesity drug maker cut ...
A Medicare experiment could change who gets Ozempic
A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.